María Victoria
Mateos Manteca
Profesora Titular de Universidad
![Foto de María Victoria](/img/nophoto.png)
![Foto de Clínica Universitaria de Navarra](/img/noimage_org.png)
Clínica Universitaria de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (22)
2024
-
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology
-
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection
Haematologica, Vol. 109, Núm. 6, pp. 1909-1917
-
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica, Vol. 109, Núm. 7, pp. 2219-2228
2021
2020
-
First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 26, Núm. 10, pp. 2308-2317
2019
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
-
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Blood Cancer Journal, Vol. 9, Núm. 4
-
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 8, pp. 668-677
2018
2017
-
Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma
Bone Marrow Transplantation, Vol. 52, Núm. 4, pp. 567-569
-
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: A PETHEMA/GEM trial
Leukemia, Vol. 31, Núm. 9, pp. 1922-1927
-
Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone
Haematologica, Vol. 102, Núm. 1, pp. 168-175
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Drugs, Vol. 76, Núm. 8, pp. 853-867
2015
-
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69
2010
-
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
Clinical Cancer Research, Vol. 16, Núm. 12, pp. 3260-3269
-
Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología
Medicina Clinica, Vol. 134, Núm. 6, pp. 268-278
2008
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression
Haematologica, Vol. 93, Núm. 4, pp. 560-565
2006
-
Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma
Hematological Oncology, Vol. 24, Núm. 4, pp. 205-211